Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

5(62.5%)

Phase 2

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 1(5)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07065058Phase 1Completed

A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects

Role: lead

NCT07056842Phase 1Completed

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

Role: lead

NCT06939296Phase 3Active Not Recruiting

A Research Study of VCT220 in Adult Chinese Participants With Obesity

Role: lead

NCT07349381Phase 1Recruiting

A Food-Effect Study of CX11 in Healthy Participants

Role: lead

NCT07347808Phase 1Completed

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

Role: lead

NCT07360275Phase 2Not Yet Recruiting

A Study of VCT220 in Participants With Hypertension and Obesity or Overweight